The role of correction of hypogonadism in the treatment and prophylaxis of urolithiasis in the men presenting with metabolic syndrome

Abdominal obesity is a major component of metabolic syndrome (MS) considered to be the key factor contributing to the development of testosterone deficiency (hypogonadism) in men. Bearing in mind the etiopathogenetic relationship between MS and urolithiasis (UL), the present study was undertaken for the purpose of elucidating the role of the main biochemical risk factors of metabolic syndrome in men, evaluating the influence of correction of hypogonadism on these factors, and optimization of the treatment and prevention of MS in these patients. The study included 90 men presenting with hypogonadism in whom the serum levels and renal excretion of the main lithogenic substances (uric acid, calcium, phosphates, magnesium) and urine pH were measured. At the first stage of the study, the patients were allocated to two groups. Group 1 was comprised of 52 patients with UL, group 2 consisted of 38 patients without UL. The patients of group 1 were found to suffer hyperuricemia (the serum uric acid levels 430 mcmol/l and higher). The patients of both groups exhibited hyperuricosuria (daily uric acid excretion over 4.13 mmol/24 hr) with the urine pH value of 5.5 and lower. The serum uric acid concentration was shown to positively correlate with the insulin and C-peptide levels. At the second stage of the study, 65 randomly selected patients were divided into two groups in one of which (n=40) they were given testosterone therapy. Compensation of hypogonadism in these patients was associated with a significant reduction of the serum uric acid levels and its daily excretion, an increase and normalization of urine pH, and a rise in the serum magnesium concentration, Similar significant changes of the same parameters were absent in the control subjects (n=25). Moreover, testosterone therapy improved characteristics of lipid and carbohydrate metabolism, caused reduction in the body weight, BMI, and the severity of insulin resistance.

metabolic syndrome (MS), urolithiasis (UL), abdominal obesity, hypogonadism, insulin resistance, hyperinsulinemia

1. Ожирение и избыточная масса тела. Информационный бюллетень ВОЗ N311, Январь 2015 г. URL: http://www.who.int/mediacentre/factsheets/fs311/ru/ (Дата обращения 20.01.15).

2. The Human Mortality Database (HMD). University of California, Berkeley and Max Planck Institute for Demographic Research. URL: http://www.mortality.org (Дата обращения 20.01.2015).

3. Reaven GM. Role of Insulin Resistance in Human Disease. Diabetes. 1988;37(12):1595-1607. doi: 10.2337/diab.37.12.1595.

4. Armellini F, Zamboni M, Bosello O. Hormones and body composition in humans: clinical studies. // International Journal of Obesity. 2000;24:S18-S21. doi: 10.1038/sj.ijo.0801270.

5. Dobs AS, Bachorik PS, Arver S, et al. Interrelationships among Lipoprotein Levels, Sex Hormones, Anthropometric Parameters, and Age in Hypogonadal Men Treated for 1 Year with a Permeation-Enhanced Testosterone Transdermal System1. // The Journal of Clinical Endocrinology & Metabolism. 2001;86(3):1026-1033. doi: 10.1210/jcem.86.3.7285.

6. Wang C, Swerdloff RS, Iranmanesh A, et al. Transdermal Testosterone Gel Improves Sexual Function, Mood, Muscle Strength, and Body Composition Parameters in Hypogonadal Men. // The Journal of Clinical Endocrinology & Metabolism. 2000;85(8):2839-2853. doi: 10.1210/jcem.85.8.6747.

7. Katznelson L, Finkelstein JS, Schoenfeld DA, et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. // The Journal of Clinical Endocrinology & Metabolism. 1996;81(12):4358-4365. doi: 10.1210/jcem.81.12.8954042.

8. Wu FCW, Tajar A, Beynon JM, et al. Identification of Late-Onset Hypogonadism in Middle-Aged and Elderly Men. // New England Journal of Medicine. 2010;363(2):123-135. doi: 10.1056/NEJMoa0911101.

9. Hall SA, Esche GR, Araujo AB, et al. Correlates of Low Testosterone and Symptomatic Androgen Deficiency in a Population-Based Sample. // The Journal of Clinical Endocrinology & Metabolism. 2008;93(10):3870-3877. doi: 10.1210/jc.2008-0021.

10. Corona G, Monami M, Rastrelli G, et al. Testosterone and Metabolic Syndrome: A Meta-Analysis Study. // The Journal of Sexual Medicine. 2011;8(1):272-283. doi: 10.1111/j.1743-6109.2010.01991.x.

11. West B, Luke A, Durazo-Arvizu RA, et al. Metabolic Syndrome and Self-Reported History of Kidney Stones: The National Health and Nutrition Examination Survey (NHANES III) 1988-1994. // American Journal of Kidney Diseases. 2008;51(5):741-747. doi: 10.1053/j.ajkd.2007.12.030.

12. Seitz C, Fajkovic H. Epidemiological gender-specific aspects in urolithiasis. // World Journal of Urology. 2013;31(5):1087-1092. doi: 10.1007/s00345-013-1140-1.

13. Лопаткин Н.А., Перепанова Т.С. Рациональная фармакотерапия в урологии. - М.: Литтерра; 2006; 466.

14. European Association of Urology Guidelines on urolithiasis 2014. URL: http://uroweb.org/wp-content/uploads/22-Urolithiasis_LR.pdf (Дата обращения 20.01.2015).

15. Scales CD, Smith AC, Hanley JM, Saigal CS. Prevalence of Kidney Stones in the United States. // European Urology. 2012;62(1):160-165. doi: 10.1016/j.eururo.2012.03.052.

16. Голованов С.А., Сивков А.В., Дзеранов Н.К. и др. Распространенность метаболических типов мочекаменной болезни в московском регионе: исследование II «Сравнительный анализ за период с 2005 по 2009 г.». // Экспериментальная и клиническая урология. 2011;1:34-8.

17. Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. // Diabetic Medicine. 2006;23(5):469-480. doi: 10.1111/j.1464-5491.2006.01858.x.